AbbVie in Talks to Acquire Revolution Medicines for $20 Billion
AbbVie is negotiating the acquisition of Revolution Medicines, valued at over $20 billion. This move aligns with AbbVie's strategy to diversify following Humira's patent expiration. The market reacted positively, boosting both companies' shares.
Insights:
AbbVie Inc. is in advanced discussions to acquire Revolution Medicines Inc. , a prominent cancer-drug developer, in a deal potentially valued at over $20 billion, including a typical acquisition premium. This strategic move, reported by the Wall Street Journal and cited by Reuters, underscores AbbVie's ongoing efforts to diversify its portfolio following the expiration of its flagship rheumatoid arthritis treatment, Humira.
